What is Cerenion Oy?
Cerenion Oy operates at the intersection of artificial intelligence and clinical neurology, specializing in advanced brain monitoring solutions. The company's flagship product, C-Trend, represents a significant advancement in the interpretation of electroencephalogram (EEG) data. By distilling complex neurological signals into actionable numerical parameters, the software empowers healthcare professionals in intensive care units to monitor patients for seizures and cerebral hypoxia with unprecedented clarity.
The company's market position is bolstered by its CE-marked technology, which ensures compliance with rigorous European safety and quality standards. By simplifying the bedside monitoring process, Cerenion addresses a critical gap in acute care, where rapid, accurate data interpretation is essential for improving patient outcomes and reducing the cognitive load on medical staff.
How much funding has Cerenion Oy raised?
Cerenion Oy has raised a total of $1.6M across 1 funding round:
Angel/Seed
$1.6M
Angel/Seed (2019): $1.6M with participation from Icebreaker and Springvest
Key Investors in Cerenion Oy
Icebreaker
A venture capital firm specializing in early-stage technology investments with a focus on Nordic and Baltic startups.
Springvest
An investment company that provides growth capital and strategic support to innovative Finnish enterprises.
What's next for Cerenion Oy?
With the backing of major strategic investment, Cerenion Oy is expected to focus on the commercial expansion of its C-Trend platform across European healthcare systems. The company's roadmap likely includes further clinical validation studies and the integration of its AI-driven diagnostics into standard intensive care protocols. As the firm scales, it will likely prioritize partnerships with hospital networks and medical device manufacturers to embed its software into existing bedside monitoring hardware. This phase of growth will be critical in establishing Cerenion as a standard-bearer for neurological monitoring in high-acuity settings, ultimately driving long-term value for stakeholders and improving the standard of care for critically ill patients.
See full Cerenion Oy company page
